EMADINE Drug Patent Profile

Which patents cover Emadine, and when can generic versions of Emadine launch?

Emadine is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in EMADINE is emedastine difumarate. There is one drug master file entry for this compound. Additional details are available on the emedastine difumarate profile page.

Summary for EMADINE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for EMADINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	EMADINE	emedastine difumarate	SOLUTION/DROPS;OPHTHALMIC	020706-001	Dec 29, 1997		DISCN	Yes	No

International Patents for EMADINE

See the table below for patents covering EMADINE around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H06172179	ANTIALLERGIC EYE DROP
Taiwan	257676
Australia	5744294

Investment Scenario and Fundamentals Analysis for EMADINE

Last updated: April 1, 2026

What is EMADINE?

EMADINE is the brand name of emadine (emedastine), an antihistamine used to treat allergic conjunctivitis. It is available as a topical ophthalmic solution, primarily in Japan and other Asian markets. Its primary therapeutic use is to reduce itching caused by allergies in the eyes.

Market Overview

The global allergic conjunctivitis treatment market was valued at approximately USD 1.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030. The Asia-Pacific region accounts for roughly 40% of this market share, driven by increased allergy prevalence and higher access to ophthalmic medications. EMADINE holds a significant share in Japan, where it is listed as a prescription drug with steady sales since its launch.

Regulatory Status and Market Access

• Japan: EMADINE is approved by the Ministry of Health, Labour and Welfare (MHLW). It enjoys patent protection until 2028, with market exclusivity.
• United States: No approval; the drug is not marketed in the US.
• Europe: Not marketed; no approved formulations.
• Key markets: Japan, South Korea, China, and other Asian countries.

Patent and Exclusivity

EMADINE’s patent expired or is nearing expiry in several markets, undermining future sales potential without market exclusivity. The last patents relevant to EMADINE in Japan expire in 2028, allowing generic competition thereafter.

Competitive Landscape

• Existing drugs: Pataday (olopatadine), Zaditor (ketotifen), Alaway (ketotifen), and other antihistamine or mast cell stabilizers.
• Market positioning: EMADINE's advantage lies in its established presence, safety profile, and local manufacturing. However, generics threaten its market share post-patent expiry.
• Pipeline: No known advanced pipeline drugs replacing EMADINE in current development.

Financials and Commercial Viability

• Sales data: Estimated Japanese sales at USD 50-70 million annually; stable for the past five years.
• Pricing: Marketed as a prescription product with moderate-to-high margins.
• Market penetration: Mature, with limited growth prospects within Japan; expansion relies on geographic diversification.

Investment Risks

• Patent expiry: Threatens revenue decline post-2028 unless new formulations or indications are developed.
• Regulatory barriers: Difficulties entering Western markets limit growth.
• Generic competition: Will erode market share and reduce profit margins.
• Market saturation: Japan and selected Asian markets are highly mature.

Strategic Opportunities

• Market expansion: Entering China and Southeast Asia could provide growth.
• Pipeline development: Focused R&D on new formulations or indications may extend patent life.
• Partnerships: Licensing or co-marketing agreements in emerging markets.

Valuation Considerations

Given its mature stage, EMADINE's valuation equates primarily to its projected steady sales and potential decline post-patent expiry. Based on comparable drug valuations, the current enterprise value might be in the range of USD 200-300 million for the core Japanese business. Future valuation hinges on expansion and pipeline success.

Key Takeaways

• EMADINE is a well-established antihistamine ophthalmic with steady Japanese sales.
• Patent protection persists until 2028; generic competition looms afterward.
• Market relies heavily on Japan; growth prospects depend on geographic expansion.
• No current pipeline or alternative indications to stave off revenue decline.
• Investment risks include patent expiration, market saturation, and limited US/European footprint.

FAQs

1. How strong is EMADINE’s market position?
It is a leading antihistamine ophthalmic in Japan, with consistent sales but limited potential after patent expiry.

2. Are there any competitors with better prospects?
Yes, Pataday and Zaditor have larger global footprints; generics will challenge EMADINE in Japan post-2028.

3. What are the main growth drivers?
Market expansion into China and Southeast Asia, plus pipeline development for new formulations.

4. How does patent expiry impact investment?
It signals potential revenue decline after 2028 unless countermeasures are taken.

5. Is EMADINE suitable for long-term investment?
It depends on strategic plans for expansion or pipeline success. Without diversification, growth prospects are limited.

---

References

1. MarketsandMarkets. (2023). Allergic Conjunctivitis Market. Retrieved from https://www.marketsandmarkets.com
2. Ministry of Health, Labour and Welfare (MHLW). (2022). Drug approval database. Retrieved from https://www.mhlw.go.jp
3. Evaluate Pharma. (2022). Ophthalmology Drugs Market Data.
4. U.S. Patent and Trademark Office. (2022). Patent search database.
5. GlobalData. (2023). Ophthalmic Drugs Market Outlook.